The American journal of the medical sciences
-
Review Case Reports
Capnocytophaga canimorsus sepsis with associated thrombotic thrombocytopenic purpura.
Capnocytophaga canimorsus, a bacterium commonly transmitted via dog bites, is known to cause sepsis in immunocompromised patients. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are rare complications of infection. The authors present a case of C canimorsus sepsis and thrombotic thrombocytopenic purpura in an asplenic patient and review the relevant literature.
-
This study was performed to investigate the impact of a family history of type 2 diabetes (T2DM) on insulin resistance and beta-cell dysfunction in populations with varying glucose tolerance. ⋯ This study showed that the pathophysiological changes were different between individuals with and without a family history of T2DM during the glucose tolerance aggravation.
-
A decade ago, hepcidin, an antimicrobial peptide with iron-regulatory properties, was discovered and proposed as playing a significant role in the pathogenesis of anemia of chronic disease. Subsequent studies have demonstrated that hepcidin is the keystone of the linked systems of iron balance and iron transport in health and in disease. The definition of the role of hepcidin and its regulation has permitted the mechanisms of disorders of iron homeostasis to be understood at a molecular level. Future studies may identify roles for hepcidin or hepcidin-related molecules in diagnosis and therapy.
-
Review Meta Analysis
Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
The objective of this study was to conduct a meta-analysis of randomized controlled trials (RCTs) to present a profound review and an objective appraisal of the efficacy and safety of the mammalian target of rapamycin (mTOR) inhibitor therapy in patients with autosomal dominant polycystic kidney disease (ADPKD). ⋯ Based on the current limited clinical trials, this study suggests that short-duration mTOR inhibitor therapy is relatively safe to slow down the increase in kidney volume in patients with early-stage ADPKD, but it has limited impact on slowing down the decrease in GFR.